These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21378393)

  • 1. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts.
    Bastin J; Lopes-Costa A; Djouadi F
    Hum Mol Genet; 2011 May; 20(10):2048-57. PubMed ID: 21378393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
    Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
    Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation sequencing of RNA reveals novel targets of resveratrol with possible implications for Canavan disease.
    Dembic M; Andersen HS; Bastin J; Doktor TK; Corydon TJ; Sass JO; Lopes Costa A; Djouadi F; Andresen BS
    Mol Genet Metab; 2019 Jan; 126(1):64-76. PubMed ID: 30446350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts.
    Aires V; Delmas D; Le Bachelier C; Latruffe N; Schlemmer D; Benoist JF; Djouadi F; Bastin J
    Orphanet J Rare Dis; 2014 Jun; 9():79. PubMed ID: 24898617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-chain fatty acid oxidation during early human development.
    Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
    Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.
    Djouadi F; Bonnefont JP; Thuillier L; Droin V; Khadom N; Munnich A; Bastin J
    Pediatr Res; 2003 Oct; 54(4):446-51. PubMed ID: 12840153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol-Induced Changes in MicroRNA Expression in Primary Human Fibroblasts Harboring Carnitine-Palmitoyl Transferase-2 Gene Mutation, Leading to Fatty Acid Oxidation Deficiency.
    Aires V; Delmas D; Djouadi F; Bastin J; Cherkaoui-Malki M; Latruffe N
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29271911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new AMPK activator, GSK773, corrects fatty acid oxidation and differentiation defect in CPT2-deficient myotubes.
    Boufroura FZ; Le Bachelier C; Tomkiewicz-Raulet C; Schlemmer D; Benoist JF; Grondin P; Lamotte Y; Mirguet O; Mouillet-Richard S; Bastin J; Djouadi F
    Hum Mol Genet; 2018 Oct; 27(19):3417-3433. PubMed ID: 30007356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet.
    Alberdi G; Rodríguez VM; Macarulla MT; Miranda J; Churruca I; Portillo MP
    Nutrition; 2013 Mar; 29(3):562-7. PubMed ID: 23274094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?
    Djouadi F; Aubey F; Schlemmer D; Gobin S; Laforet P; Wanders RJ; Strauss AW; Bonnefont JP; Bastin J
    J Inherit Metab Dis; 2006; 29(2-3):341-2. PubMed ID: 16763897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.
    Djouadi F; Aubey F; Schlemmer D; Bastin J
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1791-7. PubMed ID: 15613406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of L-aminocarnitine, an inhibitor of fatty acid oxidation.
    Chegary M; Te Brinke H; Doolaard M; Ijlst L; Wijburg FA; Wanders RJ; Houten SM
    Mol Genet Metab; 2008 Apr; 93(4):403-10. PubMed ID: 18077198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
    Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
    Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy.
    Gobin-Limballe S; Djouadi F; Aubey F; Olpin S; Andresen BS; Yamaguchi S; Mandel H; Fukao T; Ruiter JP; Wanders RJ; McAndrew R; Kim JJ; Bastin J
    Am J Hum Genet; 2007 Dec; 81(6):1133-43. PubMed ID: 17999356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.
    Yamaguchi S; Li H; Purevsuren J; Yamada K; Furui M; Takahashi T; Mushimoto Y; Kobayashi H; Hasegawa Y; Taketani T; Fukao T; Fukuda S
    Mol Genet Metab; 2012 Sep; 107(1-2):87-91. PubMed ID: 22841441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial infarction in rats causes partial impairment in insulin response associated with reduced fatty acid oxidation and mitochondrial gene expression.
    Amorim PA; Nguyen TD; Shingu Y; Schwarzer M; Mohr FW; Schrepper A; Doenst T
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):1160-7. PubMed ID: 20850803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
    Djouadi F; Bastin J
    J Inherit Metab Dis; 2008 Apr; 31(2):217-25. PubMed ID: 18392740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Food withdrawal lowers energy expenditure and induces inactivity in long-chain fatty acid oxidation-deficient mouse models.
    Diekman EF; van Weeghel M; Wanders RJ; Visser G; Houten SM
    FASEB J; 2014 Jul; 28(7):2891-900. PubMed ID: 24648546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial.
    Storgaard JH; Løkken N; Madsen KL; Voermans NC; Laforêt P; Nadaj-Pakleza A; Tard C; van Hall G; Vissing J; Ørngreen MC
    J Inherit Metab Dis; 2022 May; 45(3):517-528. PubMed ID: 35066899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study.
    Karunanidhi A; Van't Land C; Rajasundaram D; Grings M; Vockley J; Mohsen AW
    J Inherit Metab Dis; 2022 May; 45(3):541-556. PubMed ID: 35076099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.